IRIX (IRIDEX) EV-to-EBIT: -9.26 (As of Jul. 13, 2026)


IRIX IRIDEX Corp IRIX
62 GF Score
Price $1.11
GF Value $1.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is IRIDEX EV-to-EBIT?

IRIDEX IRIX -2.65% 62 EV-to-EBIT is -9.26 as of Jul. 13, 2026. GuruFocus rates IRIX with a GF Score™ of 62/100 and a GF Value™ of $1.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, IRIDEX ranks worse than 214132.55% on this metric.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, IRIDEX's Enterprise Value is $24.92 Mil. IRIDEX's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.69 Mil. Therefore, IRIDEX's EV-to-EBIT for today is -9.26.

The historical rank and industry rank for IRIDEX's EV-to-EBIT or its related term are showing as below:

IRIX' s EV-to-EBIT Range Over the Past 10 Years
Min: -154.31   Med: -3.86   Max: 389.63
Current: -9.26

During the past 13 years, the highest EV-to-EBIT of IRIDEX was 389.63. The lowest was -154.31. And the median was -3.86.

IRIX's EV-to-EBIT is ranked worse than
100% of 467 companies
in the Medical Devices & Instruments industry
Industry Median: 18.49 vs IRIX: -9.26

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. IRIDEX's Enterprise Value for the quarter that ended in Mar. 2026 was $23.25 Mil. IRIDEX's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.69 Mil. IRIDEX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -11.57%.


IRIDEX  (NAS:IRIX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

IRIDEX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2026 ) =EBIT / Enterprise Value (Q: Mar. 2026 )
=-2.69/23.24995
=-11.57 %

IRIDEX's Enterprise Value for the quarter that ended in Mar. 2026 was $23.25 Mil.
IRIDEX's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRIDEX EV-to-EBIT Related Terms


IRIDEX EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for IRIDEX's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRIDEX EV-to-EBIT Chart

IRIDEX Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.06 -2.65 -4.14 -3.64 -9.43

IRIDEX Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.81 -5.44 -8.06 -9.43 -8.64

IRIX vs ICCM, LFWD, GTHP: EV-to-EBIT Comparison

For the Medical Devices subindustry, IRIDEX's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IRIDEX's EV-to-EBIT falls into.


IRIX
62GF Score
IRIDEX Corp IRIX
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IRIDEX EV-to-EBIT Calculation

IRIDEX's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=24.915/-2.69
=-9.26

IRIDEX's current Enterprise Value is $24.92 Mil.
IRIDEX's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -9.26 mean?
IRIDEX (IRIX) has a EV-to-EBIT of -9.26 as of Jul. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on IRIDEX and its competitors. According to the industry distribution chart, IRIDEX ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is IRIDEX's EV-to-EBIT too high?
IRIDEX's current EV-to-EBIT is -9.26. Based on the distribution chart, IRIDEX ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, IRIDEX has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRIDEX's EV-to-EBIT compare to ICCM and LFWD?
According to the Medical Devices & Instruments industry distribution chart, IRIDEX ranks #999999 out of 467 companies for EV-to-EBIT. This places IRIDEX in the lower half of its industry. The industry median EV-to-EBIT is 18.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.49, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on IRIDEX and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRIDEX's current EV-to-EBIT is -9.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRIDEX stock overvalued right now?
Based on GuruFocus' analysis, IRIDEX (IRIX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.70, compared to a current price of $1.11 — trading 35% below its estimated fair value. The current EV-to-EBIT is -9.26. IRIDEX's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For IRIDEX (IRIX), the current EV-to-EBIT is -9.26 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRIDEX (IRIX) Overvalued in 2026?

Based on GuruFocus' analysis, IRIDEX stock appears to be undervalued. The current stock price of $1.11 is trading 35% below its estimated GF Value™ of $1.70. GuruFocus considers IRIDEX to be Possible Value Trap.

Key valuation signals for IRIX:

  • EV-to-EBIT: -9.26
  • GF Value™: $1.70 vs. price of $1.11 (35% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the IRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IRIDEX Business Description

Address 1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
62GF Score

Get the complete analysis for IRIX

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.11
Price
$1.70
GF Value